A liquid crystal of ascorbyl palmitate, used as vaccine platform, provides sustained release of antigen and has intrinsic pro-inflammatory and adjuvant activities which are dependent on MyD88 adaptor protein.

SANCHEZ-VALLECILLO,MF; MINGUITO DE LA ESCALERA,M; ULLO, G; PALMA, S; GONZÁLEZ-CINTADO,L; CHIODETTI, A; AGUIRRE,MV; MORÓN, G; ALLEMANDI, D; ARDAVIN,C; PISTORESI, MC; MALETTO, B

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2015 vol. 214 p. 12 - 12

odern subunit vaccines require the development of new adjuvant strategies. Recently,32 we showed that CpG-ODN formulated with a liquid crystal nanostructure formed by self33assembly of 6-O-ascorbyl palmitate (Coa-ASC16) is an attractive system for promoting an34 antigen-specific immune response to weak antigens. Here, we showed that after35 subcutaneous injection of mice with near-infrared fluorescent dye-labeled OVA antigen36 formulated with Coa-ASC16, the dye-OVA was retained at the injection site for a longer37 period than when soluble dye-OVA was administered. Coa-ASC16 alone elicited a local38 inflammation, but how this material triggers this response has not been described yet.39 Although it is known that some materials used as a platform are not immunologically inert,40 very few studies have directly focused on this topic. In this study, we explored the41 underlying mechanisms concerning the interaction between Coa-ASC16 and the immune42 system and we found that the whole infla